Skip to content
Lower risk Drug recall · FDA · Published June 26, 2026

Dextroamphetamine Extended-Release Capsules: Label Mix-Up Risk

Lannett Company recalls 5mg extended-release dextroamphetamine capsules due to labeling error. Capsules contain only immediate-release pellets but are labeled as extended-release. No immediate action needed but check labels carefully.

Take action

Contact the company

Recalling firmLannett Company Inc.1101 C Ave W · Seymour, IN 47274-3342
✎ GovInfoNow plain-language explainer

Lannett Company is recalling 5mg extended-release dextroamphetamine capsules because they contain only immediate-release pellets but are labeled as extended-release. This mix-up could lead to incorrect dosing if taken as extended-release. Read more at govinfonow.com/recall/31175-dextroamphetamine-extended-release-capsules-label-mix-up-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/31175-dextroamphetamine-extended-release-capsules-label-mix-up-risk · Updated October 4, 2026 · FDA enforcement record: FDA #D-0660-2026

Cite this page

“Dextroamphetamine Extended-Release Capsules: Label Mix-Up Risk.” GovInfoNow, updated October 4, 2026. https://govinfonow.com/recall/31175-dextroamphetamine-extended-release-capsules-label-mix-up-risk. Based on FDA recall #D-0660-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0660-2026%22&limit=1).

The FDA announced on June 26, 2026, that Lannett Company Inc. is recalling Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules due to a labeling mix-up. The hazard involves capsules containing only immediate-release pellets while being labeled as extended-release. Owners should contact the company for a remedy.

How to tell if you have it

  • Brand: Lannett
  • Product: Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules
  • Strength: 5 mg
  • NDC: 0527-0790-37
  • Lot: 25285401A
  • Expiration Date: 04/2027
  • Quantity: 1392 bottles

The hazard

The capsules contain only immediate-release (IR) pellets while labeled as ER capsules, according to the FDA. This labeling error constitutes a Class II recall.

Context

GovInfoNow's records show Lannett Company Inc. has 13 other recalls on record since October 11, 2018. Other recent recalls of similar products include Lannett Niacin Extended-release Tablets Recall (May 27, 2026), Lannett Primidone Tablets Recall (April 24, 2026), and Lannett Niacin Extended-release Tablets Recall (October 10, 2025). Other recent recalls of similar products include Supernus Trokendi XR 25mg Capsules (July 6, 2026), Supernus Trokendi XR 50mg Capsules (August 31, 2026), and Sun Pharmaceutical Perampanel 6mg Tablets Recall (June 17, 2026).

How to tell if you have this one

Check for the label that says 'Extended-Release' but the capsules contain only immediate-release pellets. The product is 5mg, 100 capsules, with NDC number 0527-0790-37.

  • Brand
    Lann: A short, human brand name for headings (e.g.
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Label Carefully

    Look for the label that says 'Extended-Release' but the capsules contain only immediate-release pellets.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “US Nationwide.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 12 days after the firm started it.

1. Firm started the recall: Jun 26, 202612. FDA classified it Class II: Jul 2, 202623. Published in FDA’s Enforcement Report: Jul 8, 202632026
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Other Lann: A short, human brand name for headings (e.g. recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0660-2026 (June 26, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0660-2026 to see it in context.
  • Plain-language summary written by qwen3:4b on October 4, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA